Development and application of adenoviral vectors for gene therapy of cancer

被引:149
作者
Zhang, WW [1 ]
机构
[1] GenStar Therapeut Corp, San Diego, CA 92121 USA
关键词
adenoviral vector; cancer gene therapy;
D O I
10.1038/sj.cgt.7700024
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
For successful gene vaccination and therapy of cancer, it is essential to develop gene delivery vectors that can meet clinical and social requirements. The need for improved vectors was clearly manifested during the peak of the first wave of gene therapy. Adenoviral (Ad) vectors have recently drawn the attention of many of those involved in the field of gene therapy for cancer because of their practical advantages and application potential. Many experiments, innovations, preclinical studies, and clinical trials have generated an overwhelming amount of data and literature concerning this vector system. It is hoped that the comprehensive review presented here, which includes the principles, potential, capacity, and limitations of the current Ad systems, will help to further the rational development of the system. The literature in this article is organized in an attempt to emphasize Ad vector development in the aspects of technical approaches, practical hurdles and strategies to overcome them, significant experimental results, recent advances, future directions, etc. The technical range of this review covers details that are intended to serve as a reference for advanced technical readers and provide a foundation for initiates in the field of Ad vector gene therapy. The material presented here is also intended for nontechnical persons who want to have an overview of the significance and potential of the technology.
引用
收藏
页码:113 / 138
页数:26
相关论文
共 241 条
  • [31] RESPIRATORY DISEASE AND ADENOVIRUSES
    BUESCHER, EL
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1967, 51 (03) : 769 - &
  • [32] STABLE EXPRESSION OF THE WILD-TYPE P53 GENE IN HUMAN LUNG-CANCER CELLS AFTER RETROVIRUS-MEDIATED GENE-TRANSFER
    CAI, DW
    MUKHOPADHYAY, T
    LIU, YJ
    FUJIWARA, T
    ROTH, JA
    [J]. HUMAN GENE THERAPY, 1993, 4 (05) : 617 - 624
  • [33] Casjens S, 1985, VIRUS STRUCTURE ASSE, P75
  • [34] INITIATION OF ADENOVIRUS DNA-REPLICATION - DETECTION OF COVALENT COMPLEXES BETWEEN NUCLEOTIDE AND THE 80-KILODALTON TERMINAL PROTEIN
    CHALLBERG, MD
    OSTROVE, JM
    KELLY, TJ
    [J]. JOURNAL OF VIROLOGY, 1982, 41 (01) : 265 - 270
  • [35] Chang JY, 1996, ONCOGENE, V13, P1405
  • [36] CHANOCK RM, 1966, JAMA-J AM MED ASSOC, V196, P445
  • [37] Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
    Chartier, C
    Degryse, E
    Gantzer, M
    Dieterle, A
    Pavirani, A
    Mehtali, M
    [J]. JOURNAL OF VIROLOGY, 1996, 70 (07) : 4805 - 4810
  • [38] Persistence in muscle of an adenoviral vector that lacks all viral genes
    Chen, HH
    Mack, LM
    Kelly, R
    Ontell, M
    Kochanek, S
    Clemens, PR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) : 1645 - 1650
  • [39] Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter
    Chen, L
    Chen, DS
    Manome, Y
    Dong, YH
    Fine, HA
    Kufe, DW
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) : 2775 - 2782
  • [40] COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4
    CHEN, LP
    ASHE, S
    BRADY, WA
    HELLSTROM, I
    HELLSTROM, KE
    LEDBETTER, JA
    MCGOWAN, P
    LINSLEY, PS
    [J]. CELL, 1992, 71 (07) : 1093 - 1102